Posted by Michael Wonder on 20 Feb 2018
SMC approves NHS funding for UCB’s Vimpat in children
20 February 2018 - Children living in Scotland with epilepsy will get NHS-funded treatment with UCB’s Vimpat following a green light from cost regulators.
The Scottish Medicines Consortium has accepted Vimpat (lacosamide) for NHS use as an adjunctive therapy for partial-onset (focal) seizures with or without secondary generalisation in children aged four years and older.
In Scotland there are around 55,000 people living with epilepsy but, despite its high prevalence, around 10-29 percent of children with the condition experience inadequate seizure control with currently available anti-epileptic drugs.
